Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis

Launched by ASSIUT UNIVERSITY · Aug 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a substance called Interleukin 33 (IL-33) and its connection to a condition known as Ankylosing Spondylitis (AS). AS is a type of arthritis that primarily affects the spine, leading to pain and stiffness. Researchers want to learn how levels of IL-33 in people with AS relate to subclinical atherosclerosis, which is a condition where plaque builds up in the arteries but hasn't yet caused any noticeable heart problems. To do this, they will measure something called carotid intima-media thickness (CIMT) using a special ultrasound test on the neck.

If you are between 20 and 40 years old and have been diagnosed with Ankylosing Spondylitis, you might be eligible to participate. However, the study will not include people who have other types of rheumatic diseases, have experienced certain heart-related issues recently, or have other factors that could increase their risk for artery problems. The trial is not recruiting participants just yet, but if you join, you can expect to undergo tests to measure IL-33 levels and to check the health of your arteries. This research could help us better understand how AS affects heart health and lead to better care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient diagnosed as Ankylosing Spondylitis
• • Age (20-40)
• Exclusion Criteria:
• • Patients with other rheumatic diseases/other SPA types
• • Participants with history of CVD event in past or present
• • Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
• • Patient with other risk factor for atherosclerosis.